Compounds and their use
AssigneesAstraZeneca AB, Mitsubishi Tanabe Pharma Corporation
InventorsLars Anders Mikael Johansson, Giulia Bergonzini, Henrik Gradén, Hiroshi Sugama, Takehiko Matsumura
Life of this patent
Estimating the term…
Abstract
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.
Claims30
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein
- R1 is selected from
- each R3 is independently selected from —H and —C1-3 alkyl;
- R4 is selected from —H and —C1-3 alkyl;
- R2A, R2B, R2C, and R2D are each independently selected from —H, —F, —Cl, —C1-3 alkyl substituted with 0-3 —F substituents, cyclopropyl, —OCF3, and —SO2Me;
- W, X, Y and Z are each independently selected from CR5 and N;
- zero or one of W, X, Y and Z are N, and the remainder of W, X, Y, and Z are CR5;
- each R5 is independently selected from —H, -Me, and —F.
Dependencies are inferred from the claim text.